What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?

ABSTRACT:

Objective

To investigate the prognostic value of t(11;14) for de novo multiple myeloma (MM) patients in novel agent era.

Methods

A total of 455 patients with fluorescence in situ hybridization (FISH), before treatments from three hospitals in China, were included in the study. All patients received autologous stem cell transplantation (ASCT) after induction therapy as consolidation. High risk (HR) cytogenetics were defined as t(4;14), t(14;16), and/or del 17p.

Results

A total of 152 patients were in the HR group. Of patients without HR cytogenetics, 55 were in the t(11;14) group, and 248 were in the standard risk (SR) group without t(11;14). Gain in 1q21 was observed in 38.9% patients with t(11;14). There were no differences in median progression free su

SUBMITTER: Gao W 

PROVIDER: S-EPMC7649769 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature